|
Rheuminations: Arthritis Tx the EULAR Way
MedPage Today The American College of Rheumatology (ACR) guidelines state that “if after 3 months of methotrexate monotherapy or DMARD combination therapy … the panel recommends adding or switching to an anti-TNF biologic, abatacept, or rituximab [Rituxan].”. |
Obesity at age 20 associated with increased risk of multiple sclerosis – Clinical Endocrinology News Digital Network
Obesity at age 20 associated with increased risk of multiple sclerosisClinical Endocrinology News Digital Network… 7-year period and 2,017 control subjects completed detailed questionnaires concerning environmental exposures and other factors. The co…
Genetically Mutated Mice Capable of Avoiding HIV Infection – Nature World News
Nature World NewsGenetically Mutated Mice Capable of Avoiding HIV InfectionNature World NewsMice that have been genetically reprogrammed to have human-like immune systems can be protected from HIV by boosting their production of certain broadly neutral…
Mini-VADs could transform heart failure therapy – Family Practice News Digital Network
|
Mini-VADs could transform heart failure therapy
Family Practice News Digital Network SNOWMASS, COLO. – Survival in patients with advanced heart failure who receive a left ventricular assist device as destination therapy or as a bridge to transplant has increased dramatically in recent years – and the best may be yet to come. “There is … |
RA Treatment: When Biologic Fails – MedPage Today
RA Treatment: When Biologic FailsMedPage TodayThe most commonly used non-TNF agents in RA are rituximab (Rituxan), a B-cell-depleting monoclonal antibody, abatacept (Orencia), a selective T-cell costimulation modulator, and tocilizumab (Actemra), a mon…
Arbitration hearing dead ahead for Josh Tomlin, Cleveland Indians – The Plain Dealer
|
Arbitration hearing dead ahead for Josh Tomlin, Cleveland Indians
The Plain Dealer He followed that by going 5-8 with a 6.36 ERA in 2012 before undergoing ligament transplant surgery on his elbow on Aug. 13. This spring Tomlin will compete for the fifth spot in the rotation with Trevor Bauer and Carlos Carrasco. “I feel great … |
Kidney Transplant: Donors May Risk ESRD – MedPage Today
|
Kidney Transplant: Donors May Risk ESRD
MedPage Today Genetics is a powerful risk factor and, until it is taken into account, it is difficult to blame the nephrectomy for the increased risk.” He said a more accurate way to assess outcomes would be to have a control group of relatives who do not donate an … |
Exposure to iron mines doesn't cause fatal lung diseases, doctors say – Times of India
Firstpost |
Exposure to iron mines doesn’t cause fatal lung diseases, doctors say
Times of India PANAJI: Lung diseases caused in workers employed in iron ore mines and those living near the mines are reversible and not fatal in nature, doctors said, speaking ahead of the opening of the 64th national conference of Indian association of occupational … Iron ore mining doesn’t cause lung problems: expertsBusiness Standard Iron ore mining doesn’t cause fatal health problems, claim expertsFirstpost |
FDA to Investigate Diabetes Drug Saxagliptin for Possible Heart Failure Risk – U.S. News & World Report
The Pharma Letter |
FDA to Investigate Diabetes Drug Saxagliptin for Possible Heart Failure Risk
U.S. News & World Report TUESDAY, Feb. 11, 2014 (HealthDay News) — The U.S. Food and Drug Administration announced Tuesday that it will investigate possible links between the diabetes drug saxagliptin and a heightened risk for heart failure among users. In a statement, the … FDA Investigating Heart Failure Risk Linked To OnglyzaForbes FDA to review heart failure risk associated with saxagliptinHealio FDA to review heart failure risk with AstraZeneca diabetes drugThe Pharma Letter Clinical Endocrinology News Digital Network –Science World Report –MedPage Today all 39 news articles » |
FDA Investigating Heart Failure Risks with Saxagliptin – Drug Discovery & Development
Drug Discovery & Development |
FDA Investigating Heart Failure Risks with Saxagliptin
Drug Discovery & Development The U.S. Food and Drug Administration (FDA) has requested clinical trial data from the manufacturer of saxagliptin, which is co-developed by AstraZeneca and Bristol-Myers Squibb Co., to investigate a possible association between use of the type 2 … |